PL1841433T3 - Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego - Google Patents

Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego

Info

Publication number: PL1841433T3
Authority: PL; Poland
Prior art keywords: composition; nervous system; central nervous; system disorders; treating central
Prior art date: 2005-01-27

Application number

PL06712847T

Other languages

English (en)

Inventor

Ryuji Ueno

Original Assignee

Sucampo Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-27

Filing date

2006-01-26

Publication date

2012-07-31

2006-01-26 Application filed by Sucampo Ag filed Critical Sucampo Ag

2012-07-31 Publication of PL1841433T3 publication Critical patent/PL1841433T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL06712847T 2005-01-27 2006-01-26 Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego PL1841433T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64700805P	2005-01-27	2005-01-27
EP06712847A EP1841433B1 (en)	2005-01-27	2006-01-26	Composition for treating central nervous system disorders
PCT/JP2006/301704 WO2006080549A2 (en)	2005-01-27	2006-01-26	Method and composition for treating central nervous system disorders

Publications (1)

Publication Number	Publication Date
PL1841433T3 true PL1841433T3 (pl)	2012-07-31

Family

ID=36740907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06712847T PL1841433T3 (pl)	2005-01-27	2006-01-26	Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego

Country Status (20)

Country	Link
US (2)	US8202909B2 (pl)
EP (2)	EP2332545A1 (pl)
JP (1)	JP5147404B2 (pl)
KR (1)	KR101354771B1 (pl)
CN (1)	CN101146541B (pl)
AR (1)	AR055846A1 (pl)
AU (1)	AU2006209072B2 (pl)
BR (1)	BRPI0607084A2 (pl)
CA (1)	CA2595898C (pl)
DK (1)	DK1841433T3 (pl)
ES (1)	ES2375082T3 (pl)
HK (1)	HK1118716A1 (pl)
IL (1)	IL184578A (pl)
NO (1)	NO340257B1 (pl)
NZ (1)	NZ556710A (pl)
PL (1)	PL1841433T3 (pl)
PT (1)	PT1841433E (pl)
RU (1)	RU2440338C2 (pl)
TW (1)	TWI384988B (pl)
WO (1)	WO2006080549A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI225398B (en) *	1999-07-14	2004-12-21	R Tech Ueno Ltd	Composition for treatment of external secretion disorders
WO2008108322A2 (en) *	2007-02-27	2008-09-12	Sucampo Ag	Composition and method for protecting mitochondria
KR101485212B1 (ko) *	2007-07-19	2015-01-22	가부시키가이샤 아루떼꾸 우에노	11-데옥시-프로스타글란딘 화합물을 포함하는 약학 조성물 및 상기 화합물을 안정화시키는 방법
US8871752B2 (en)	2008-02-19	2014-10-28	Sucampo Ag	Method for modulating stem cell growth
US9084815B2 (en)	2009-09-16	2015-07-21	Sucampo Ag	Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
BR112013009163A2 (pt) *	2010-10-15	2016-07-26	Scinopharm Kunshan Biochemical Technology Co Ltd	processo para preparação de lubiprostona
US9259409B2 (en)	2011-01-24	2016-02-16	Inceptum Research & Therapeutics, Inc.	Compositions comprising a prostaglandin for treating neuropsychiatric conditions
RU2013151166A (ru) *	2011-04-19	2015-05-27	Сукампо Аг	Способ модуляции активности цитокинов
NZ620300A (en) *	2011-08-05	2015-09-25	Sucampo Ag	Method for treating schizophrenia
WO2014159679A1 (en)	2013-03-12	2014-10-02	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods for using lubiprostone to absorb fluid from the subretinal space
AU2015334964B2 (en) *	2014-10-21	2019-06-20	Universitat De Les Illes Balears	Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1120243A (en)	1970-03-09	1968-07-17	Samuelsson Bengt	Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr)	1971-07-14	1973-01-15	American Cyanamid Co	Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) *	1975-09-02	1977-07-27	Upjohn Co	Prostanoic acid derivatives
SU845774A3 (ru)	1976-04-20	1981-07-07	Фармиталия Карло Эрба С.П.А. (Фирма)	Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) *	1977-07-05	1978-12-26	The Upjohn Company	6-Hydroxy-PGE1 compounds
US5166174A (en)	1987-01-28	1992-11-24	K.K. Ueno Seiyaku Oyo Kenkyujo	Prostaglandins E and anti-ulcers containing same
CA1322749C (en)	1987-01-28	1993-10-05	Ryuzo Ueno	Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en)	1987-04-30	1993-06-22	R-Tech Ueno, Ltd.	Prostaglandins of the F series
US5317032A (en)	1987-10-02	1994-05-31	Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo	Prostaglandin cathartic
CA2030345C (en)	1989-11-22	1998-12-08	Ryuji Ueno	Use of 15-keto-prostaglandin compound for improvement of encephalic function
EP0444844B1 (en)	1990-02-26	1995-01-18	R-Tech Ueno Ltd.	New 15-dehydroxy-16-oxoprostaglandins
TW224942B (pl)	1990-04-04	1994-06-11	Adka Ueno Kk
JPH04187637A (ja) *	1990-11-21	1992-07-06	Ueno Seiyaku Oyo Kenkyusho:Kk	記憶改善剤
JPH07113012B2 (ja)	1991-01-29	1995-12-06	株式会社アールテック・ウエノ	新規１５−ケト−プロスタグランジン類
JP3183615B2 (ja) *	1994-06-03	2001-07-09	株式会社アールテック・ウエノ	肝・胆道系疾患処置剤
CA2150287C (en) *	1994-06-03	2004-08-10	Ryuji Ueno	Agent for treating hepato-biliary diseases
US6242485B1 (en)	1996-06-10	2001-06-05	R-Tech Ueno	Endothelin antagonist
ES2310013T3 (es)	1997-11-28	2008-12-16	Sucampo Ag	Uso de compuestos de 15-ceto-prostaglandina e como antagonistas de endotelina.
JP3703004B2 (ja)	1998-07-15	2005-10-05	小野薬品工業株式会社	５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
AU3713600A (en) *	1999-03-01	2000-09-21	Nitromed, Inc.	Nitrosated and nitrosylated prostaglandins, compositions and metods of use
TWI225398B (en)	1999-07-14	2004-12-21	R Tech Ueno Ltd	Composition for treatment of external secretion disorders
WO2001070233A2 (en) *	2000-03-24	2001-09-27	Sucampo Ag	Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US6414016B1 (en)	2000-09-05	2002-07-02	Sucampo, A.G.	Anti-constipation composition
US20040224995A1 (en)	2003-05-09	2004-11-11	University Of North Texas Health Science Center At Fort Worth	Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) *	2003-09-08	2005-08-17	秦正红	前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

2006
- 2006-01-26 DK DK06712847.0T patent/DK1841433T3/da active
- 2006-01-26 AU AU2006209072A patent/AU2006209072B2/en not_active Ceased
- 2006-01-26 US US11/339,495 patent/US8202909B2/en not_active Expired - Fee Related
- 2006-01-26 CA CA2595898A patent/CA2595898C/en not_active Expired - Fee Related
- 2006-01-26 PL PL06712847T patent/PL1841433T3/pl unknown
- 2006-01-26 TW TW095103028A patent/TWI384988B/zh not_active IP Right Cessation
- 2006-01-26 JP JP2007535160A patent/JP5147404B2/ja not_active Expired - Fee Related
- 2006-01-26 RU RU2007132081/04A patent/RU2440338C2/ru active
- 2006-01-26 PT PT06712847T patent/PT1841433E/pt unknown
- 2006-01-26 CN CN2006800094248A patent/CN101146541B/zh not_active Expired - Fee Related
- 2006-01-26 BR BRPI0607084-1A patent/BRPI0607084A2/pt not_active Application Discontinuation
- 2006-01-26 WO PCT/JP2006/301704 patent/WO2006080549A2/en active Application Filing
- 2006-01-26 EP EP11155203A patent/EP2332545A1/en not_active Withdrawn
- 2006-01-26 KR KR1020077019366A patent/KR101354771B1/ko active IP Right Grant
- 2006-01-26 NZ NZ556710A patent/NZ556710A/en not_active IP Right Cessation
- 2006-01-26 ES ES06712847T patent/ES2375082T3/es active Active
- 2006-01-26 AR ARP060100290A patent/AR055846A1/es not_active Application Discontinuation
- 2006-01-26 EP EP06712847A patent/EP1841433B1/en active Active
2007
- 2007-07-12 IL IL184578A patent/IL184578A/en active IP Right Grant
- 2007-08-24 NO NO20074332A patent/NO340257B1/no not_active IP Right Cessation
2008
- 2008-09-18 HK HK08110344.4A patent/HK1118716A1/xx not_active IP Right Cessation
2012
- 2012-05-14 US US13/470,377 patent/US20120225938A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2595898A1 (en)	2006-08-03
RU2007132081A (ru)	2009-03-10
RU2440338C2 (ru)	2012-01-20
HK1118716A1 (en)	2009-02-20
US20060194880A1 (en)	2006-08-31
ES2375082T3 (es)	2012-02-24
AU2006209072B2 (en)	2011-02-24
NO20074332L (no)	2007-10-17
KR101354771B1 (ko)	2014-01-22
EP2332545A1 (en)	2011-06-15
IL184578A0 (en)	2007-10-31
CA2595898C (en)	2015-04-28
CN101146541A (zh)	2008-03-19
EP1841433A2 (en)	2007-10-10
TW200642690A (en)	2006-12-16
WO2006080549A3 (en)	2007-07-05
US8202909B2 (en)	2012-06-19
JP5147404B2 (ja)	2013-02-20
JP2008528440A (ja)	2008-07-31
IL184578A (en)	2015-02-26
PT1841433E (pt)	2012-02-01
NO340257B1 (no)	2017-03-27
AR055846A1 (es)	2007-09-12
DK1841433T3 (da)	2012-01-16
BRPI0607084A2 (pt)	2009-08-04
EP1841433B1 (en)	2011-11-30
CN101146541B (zh)	2012-04-11
AU2006209072A1 (en)	2006-08-03
TWI384988B (zh)	2013-02-11
KR20070107065A (ko)	2007-11-06
NZ556710A (en)	2010-08-27
WO2006080549A2 (en)	2006-08-03
US20120225938A1 (en)	2012-09-06

Publication	Publication Date	Title
PL1841433T3 (pl)	2012-07-31	Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego
EP2083857A4 (en)	2010-03-24	METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
IL186450A0 (en)	2008-01-20	Methods for treating anxiety related disorders
IL187168A0 (en)	2008-02-09	Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL180187A (en)	2011-02-28	Composition for treating inflammatory disorders
HK1157575A1 (en)	2012-07-06	Treating neurological disorders
HK1115341A1 (en)	2008-11-28	Composition for treating mental health disorders
IL185016A0 (en)	2007-12-03	Compounds for the treatment of proliferative disorders
IL178648A0 (en)	2007-02-11	Substituted morpholine compounds for the treatment of central nervous system disorders
IL190913B (en)	2020-04-30	Preparations for the treatment of sweating disorders
EP2170309A4 (en)	2010-11-03	METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
ZA200809528B (en)	2009-11-25	Treatment for depressive disorders
HK1101140A1 (en)	2007-10-12	Compositions and methods for treating neurological disorders
IL176836A0 (en)	2006-10-31	Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
ZA200809527B (en)	2009-11-25	Treatment for depressive disorders
PL1993589T3 (pl)	2014-03-31	Sposoby leczenia chorób neurologicznych
ZA200809284B (en)	2009-08-26	Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders
ZA200804951B (en)	2009-04-29	Compositions and methods for treating CNS disorders
IL198856A0 (en)	2010-02-17	Compounds useful for treating neurodegenerative disorders
IL187439A0 (en)	2008-02-09	Compounds useful for treating neurodegenerative disorders
IL162288A0 (en)	2005-11-20	Compositions and methods for treating neurodegenerative disorders
HK1118286A1 (en)	2009-02-06	Dipyrazoles as central nervous system agents
ZA200708543B (en)	2008-10-29	Methods for treating anxiety related disorders
EP1890711A4 (en)	2010-08-18	COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES
EP1942909A4 (en)	2010-01-06	METHODS OF TREATING RESPIRATORY DISORDERS